Activin type II receptor signaling in cardiac aging and heart failure
Jason D. Roh(Massachusetts General Hospital), Anthony Rosenzweig(Stanley Medical Research Institute), Ryan Hobson(Massachusetts General Hospital), Jonathan G. Seidman(Harvard University), Nicholas Houstis(Whitehead Institute for Biomedical Research), Mark D. Benson(Beth Israel Deaconess Medical Center), Estelle Lach‐Trifilieff(Novartis (Switzerland)), Ashish Yeri(Q Therapeutics (United States)), Sammy Elmariah(Brigham and Women's Hospital), Robert E. Gerszten(Beth Israel Deaconess Medical Center), Federico Damilano(Massachusetts General Hospital), Vinita Chaudhari(Massachusetts General Hospital), Colin Platt(Massachusetts General Hospital), David J. Glass(Regeneron (United States)), Vassilios J. Bezzerides(Boston Children's Museum), Michael Biersmith(The Ohio State University Wexner Medical Center), Chunyang Xiao(Xi'an Jiaotong University), Brian R. Lindman(Washington University in St. Louis), Daniel A. Zlotoff(Massachusetts General Hospital), Pablo Quintero(Beth Israel Deaconess Medical Center), Se‐Jin Lee(University of Connecticut), Christine E. Seidman(Harvard University)
Cited by 147
Related Papers
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
|Nature Genetics|2003|10.6k
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k
Cells of the adult human heart
|Nature|2020|1.8k